PPD signed on as preferred provider for Harbour BioMed

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/tadamichi)
(Image: Getty/tadamichi)

Related tags: Ppd, CRO, Preferred partnership, Clinical trials

Harbour BioMed has selected PPD as its preferred CRO partner as part of a strategic collaboration to develop novel oncology and immunology therapeutics.

The a global clinical-stage biopharmaceutical company Harbour BioMed (HBM), and contract research organization (CRO), PPD, have today announced a strategic collaboration.

As per the agreement, HBM has selected PPD as its preferred CRO partner to conduct global clinical studies. The companies have worked together previously, recently completing an Australian ethics committee (EC) submission for HBM4003, HBM’s anti-cancer immunotherapy targeting solid tumors.

“Harbour BioMed is leveraging the services of PPD Biotech, which combines the global capabilities of PPD with the hands-on approach, dedication and innovative mindset that drive the success of biotech clients,” ​said Anshul Thakral, executive vice president and global head of PPD Biotech.

“Harbour BioMed’s selection of PPD Biotech as its preferred partner is further evidence that pairing our unique biotech perspective with our scalable global development services is a powerful combination for our customers,”​ he added.

Established in late 2016, HBM’s portfolio includes five clinical-stage, in-licensed compounds as well as therapeutics generated by its internal discovery efforts.  The company also has co-discovery and development collaborations in place with academic institutions and biopharmaceutical companies.

These programs leverage HMB’s two patented transgenic mouse platforms for generating fully human monoclonal antibodies (mAb), which the company also licenses out.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars